Pharmaceutical formulation containing a biguanide and a...

Details Pharmaceutical formulation containing a biguanide and a... Pharmaceutical formulation containing a biguanide and a...

2005-03-30

2011-12-27

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C514S369000, C514S635000

Reexamination Certificate

active

08084058

ABSTRACT:
A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative and a disintegrating agent is herein disclosed and described. The dosage formulation exhibits a significant increase in bioavailability of the thiazolidinedione derivative component compared to conventional immediate release dosage forms containing only a thiazolidinedione derivative.

REFERENCES:
patent: 3174901 (1965-03-01), Sterne
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4166800 (1979-09-01), Fong
patent: 4389330 (1983-06-01), Tice et al.
patent: 4687777 (1987-08-01), Meguro et al.
patent: 4839177 (1989-06-01), Colombo et al.
patent: 4891223 (1990-01-01), Ambegaonkar et al.
patent: 4968507 (1990-11-01), Zentner et al.
patent: 5294770 (1994-03-01), Riddle et al.
patent: 5356913 (1994-10-01), Colca
patent: 5376771 (1994-12-01), Roy
patent: 5478852 (1995-12-01), Olefsky et al.
patent: 5602133 (1997-02-01), Antonucci et al.
patent: 5658474 (1997-08-01), Geerke
patent: 5681584 (1997-10-01), Savastano et al.
patent: 5698220 (1997-12-01), Cardinal et al.
patent: 5719188 (1998-02-01), Colca
patent: 5840335 (1998-11-01), Wenzel et al.
patent: 5859037 (1999-01-01), Whitcomb
patent: 5916584 (1999-06-01), O'Donoghue et al.
patent: 5948440 (1999-09-01), Arora et al.
patent: 5952356 (1999-09-01), Ikeda et al.
patent: 5955106 (1999-09-01), Moeckel et al.
patent: 5965584 (1999-10-01), Ikeda et al.
patent: 6011049 (2000-01-01), Whitcomb
patent: 6031004 (2000-02-01), Timmins et al.
patent: 6099859 (2000-08-01), Cheng et al.
patent: 6099862 (2000-08-01), Chen et al.
patent: 6153632 (2000-11-01), Rieveley
patent: 6166042 (2000-12-01), Ikeda et al.
patent: 6166043 (2000-12-01), Ikeda et al.
patent: 6172090 (2001-01-01), Ikeda et al.
patent: 6191162 (2001-02-01), Byrd et al.
patent: 6248363 (2001-06-01), Patel et al.
patent: 6291495 (2001-09-01), Rieveley
patent: 6296874 (2001-10-01), Cutie et al.
patent: 6329403 (2001-12-01), Odaka et al.
patent: 6383471 (2002-05-01), Chen et al.
patent: 6403121 (2002-06-01), Adjei et al.
patent: 6451342 (2002-09-01), Adjei et al.
patent: 6475521 (2002-11-01), Timmins et al.
patent: 6495162 (2002-12-01), Cheng et al.
patent: 6524621 (2003-02-01), Adjei et al.
patent: 6599284 (2003-07-01), Faour
patent: 6660300 (2003-12-01), Timmins et al.
patent: 6780432 (2004-08-01), Cutie et al.
patent: 6790459 (2004-09-01), Cheng et al.
patent: 6838093 (2005-01-01), Flanner et al.
patent: 6866866 (2005-03-01), Chen et al.
patent: 7374779 (2008-05-01), Chen et al.
patent: 2001/0046515 (2001-11-01), Adjei et al.
patent: 2002/0064556 (2002-05-01), Cheng et al.
patent: 2002/0071866 (2002-06-01), Geerke
patent: 2003/0077297 (2003-04-01), Chen et al.
patent: 2003/0113371 (2003-06-01), Dhawan et al.
patent: 2003/0118647 (2003-06-01), Seth
patent: 2003/0118649 (2003-06-01), Gao et al.
patent: 2003/0224046 (2003-12-01), Rao et al.
patent: 2004/0081697 (2004-04-01), Lewis et al.
patent: 2004/0092531 (2004-05-01), Chizh et al.
patent: 2005/0074490 (2005-04-01), Lin et al.
patent: 2006/0057202 (2006-03-01), Antarkar et al.
patent: 2006/0141023 (2006-06-01), Trehan et al.
patent: 2006/0204578 (2006-09-01), Vergez et al.
patent: 2006/0286168 (2006-12-01), Koike et al.
patent: 1582928 (2005-02-01), None
patent: 0 169 105 (1986-01-01), None
patent: 0 283 369 (1988-09-01), None
patent: 0 381 181 (1995-08-01), None
patent: 0 749 751 (1996-12-01), None
patent: 0 781 129 (1997-07-01), None
patent: 0 753 298 (2001-11-01), None
patent: 1 588 708 (2005-10-01), None
patent: WO 96/09823 (1996-04-01), None
patent: WO 98/11879 (1998-03-01), None
patent: WO 98/55107 (1998-12-01), None
patent: WO 99/47125 (1999-09-01), None
patent: WO 99/47128 (1999-09-01), None
patent: WO 99/55320 (1999-11-01), None
patent: WO 00/28989 (2000-05-01), None
patent: WO 00/72827 (2000-12-01), None
patent: WO 01/35940 (2001-05-01), None
patent: WO 01/35941 (2001-05-01), None
patent: WO01/47498 (2001-07-01), None
patent: WO01/74336 (2001-10-01), None
patent: WO 01/82875 (2001-11-01), None
patent: WO0211702 (2002-02-01), None
patent: WO 02/28181 (2002-04-01), None
patent: WO 03/004009 (2003-01-01), None
patent: WO 03/035029 (2003-05-01), None
patent: WO03/004355 (2003-06-01), None
patent: WO 03/047529 (2003-06-01), None
patent: WO 2004/006921 (2004-01-01), None
patent: WO 2004/067001 (2004-08-01), None
patent: WO 2005/063226 (2005-07-01), None
patent: WO 2005/110405 (2005-11-01), None
Koski, “Review of Oral Antihyperglycemic Agents,” Diabetes Educator, 32(6):869-874.
Finnish Monograph of the Diformin®, Retard tablet, with English translation.
O.J. Lucis, MD, Ph.D., MSC, Canada Medical Association J. Pharmacologic Update “The status of metformin in Canada” vol. 128, Jan. 1, 1983, pp. 24-26.
ADA Professional Section Member Supplement 0474 and 0503-506 (Poster) p. A110; A117.
ACTOS® product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175.
An opposition filed in Costa Rica against a foreign equivalent of the present application.
A translation of the opposition filed in Costa Rica against a foreign equivalent of the present application.
A response to the opposition filed in Costa Rica against a foreign equivalent of the present application.
A translation of the response to the opposition filed in Costa Rica against a foreign equivalent of the present application.
An opposition filed in Chile against a foreign equivalent of the present application.
A translation of the opposition filed in Chile against a foreign equivalent of the present application.
A response to the opposition filed in Chile against a foreign equivalent of the present application.
A translation of the response to the opposition filed in Chile against a foreign equivalent of the present application.
An English translation of an opposition filed in Columbia against a related foreign application.
A response to the opposition filed in Columbia against a related foreign application (in Spanish).
An English translation of a response to the opposition filed in Columbia against a related foreign application.
A search report from the Georgian Patent Office (and English translation).
An Office Action from the Ukrainian Patent Office (and English translation).
Efficacy of Metabolic Effects of Metformin and Troglitazone in type II diabetes mellitus; Inzucchi Se et al. N. Engl. J Med. Mar. 26, 1998; 338(13): 867-72.
Effect of Metformin and Rosiglitazone combination therapy in patients with type II diabetes mellitus, Fonseca V, et al.; Apr. 5, 2000; 283(13): 1695-702.
Zimmer Barbara, Supplementary European Search Report, EP 03 75 4689, May 6, 2010, European Patent Office 80298 Munich, Germany.
Koski, Renee Rae, Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus, The Diabetes Educator 32 (6) 869-876 (Nov./Dec. 2006).
Jagoe, Donna, International Search Report, PCT/US03/29292, Apr. 26, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.
Jagoe, Donna, International Preliminary Examination Report, PCT/US03/29292, Jan. 4, 2005, IPEA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.
Joynes, Robert M., International Search Report, PCT/US04/04112, Aug. 12, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.
Nickitas-Etienne, Athina, International Preliminary Report on Patentability, PCT/US2004/004112, Feb. 28, 2007, The International Bureau of WIPO, 34, chemin des Colombettes, 1211 Geneva 20, Switzerland.
Woodward, Michael, International Search Report and Written Opinion of the International Searching Authority, PCT/US06/09082, Jul. 20, 2006, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.
Menon, K.V, et al., Severe Cholestatic Hepatitis from Troglitazone in a Patient with Nonalcoholic Steatohepatitis and Diabetes Mellitus, The American J. of Gastroenterology, 96 (5) 1631-34 (2001).
Egger M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Melli

Affiliated with

Also associated with

Rating

Pharmaceutical formulation containing a biguanide and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical formulation containing a biguanide and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation containing a biguanide and a... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4313439